The persistence of anticardiolipin antibodies is associated with an increased risk of the presence of lupus anticoagulant and anti-β2-glycoprotein I antibodies

Rheumatology

Volumn 45, Issue 9, 2006, Pages 1116-1120

  Neville, C ^a   Rauch, J ^b   Kassis, J ^d   Solymoss, S ^b   Joseph, L ^a,c   Belisle, P ^a   Subang, R ^b   Chang, E R ^e   Fortin, P R ^e,f  

^a Division of Clinical Epidemiology   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

2 glycoprotein I antibodies.; Anti ; Anticardiolipin antibodies; Antiphospholipid antibodies; Lupus anticoagulant

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ADULT; AGE; ARTERY THROMBOSIS; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENDER; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; LOGISTIC MODELS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUEBEC; RISK; THROMBOSIS; TIME FACTORS;

EID: 33749644559     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel050     Document Type: Article

References (19)

1. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
2. Long AA, Ginsberg JS, Brill-Edwards P, Johnston M, Turner C, Denburg JA. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: A cross-sectional study. Thromb Haemost 1991;66:520-4.
3. Ishii Y, Nagasawa K, Mayumi T, Niho Y. Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus. Ann Rheum Dis 1990;49:387-90.
4. Galli M, Barbui T. Antiphospholipid antibodies and thrombosis: Strength of association. Hematol J 2003;4:180-6.
5. Galli M. Antiphospholipid antibodies and thrombosis: Do test patterns identify the patients' risk? Thromb Res 2004;114:597-601.
6. Galli M, Luciani D, Bertolini G, Barbui T. Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:17-23.
7. Detková D, Gil-Aguado A, Lavilla P, Cuesta MV, Fontán G, Pascual-Salcedo D. Do antibodies to β2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome? Lupus 1999;8:430-8.
8. Neville C, Rauch J, Kassis J, Chang ER, Joseph L, Le Comte M, Fortin PR. Thromboembolic risk in patients with high titre anti-cardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 2003;90:108-15.
9. Hudson M, Herr AL, Rauch J et al. The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol 2003;30:2385-91.
10. von Landenberg P, Scholmerich J, von Kempis J, Lackner KJ. The combination of different antiphospholipid antibody subgroups in the sera of patients with autoimmune diseases is a strong predictor for thrombosis. A retrospective study from a single center. Immunobiology 2003;207:65-71.
11. Lee EY, Lee CK, Lee TH et al. Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis? Thromb Res 2003;111:29-32.
12. Derksen W, Erkan D, Kaplan V, Sammaritano L, Lockshin MD. Real world experience with APL: Comparison between APS and asymptomatic APL-positive patients. Thrombosis Res 2004;114:635.
13. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
14. Price BE, Rauch J, Shia MA et al. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J Immunol 1996;157:2201-8.
15. Rauch J, Tannenbaum M, Neville C, Fortin PR. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin. Thromb Haemost 1998;80:936-41.
16. SAS Institute. The SAS System for Windows [8.2]. 2002. Cary, NC: SAS Institute.
17. Derksen W, Erkan D, Kaplan V, Sammaritano L, Pierangeli S, Lockshin M. Real world experience with antiphospholipid antibodies (APL): How stable are APL over time? Thromb Res 2004;114:635.
18. Fickl H, Van Antwerpen VL, Richards GA et al. Increased levels of autoantibodies to cardiolipin and oxidised low density lipoprotein are inversely associated with plasma vitamin C status in cigarette smokers. Atherosclerosis 1996;124:75-81.
19. Fortin PR, Kassis J, Neville C et al. The presence of antiphospholipid antibody predicts new thrombosis at three years in a high-risk population. Arthritis Rheum 2003;48(Suppl. 9):S364.